Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors
Authors:
- Jad ChahoudJCJad Chahoud
- Pavlos MsaouelPavlos Msaouel
- Jeremy A. RossJRJeremy A. Ross
- Tharakeswara K. BathalaTBTharakeswara K. Bathala
- Jianjun GaoJGJianjun Gao
- Robert HornRHRobert Horn
- Lianchun XiaoLXLianchun Xiao
- Kanishka SircarKSKanishka Sircar
- Matthew T. CampbellMCMatthew T. Campbell
- Amishi Y. ShahASAmishi Y. Shah
- Sangeeta GoswamiSGSangeeta Goswami
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (2) , 134.e9-134.e16
Abstract
No abstract availableKeywords
Funding Information
- Kidney Cancer Association
- U.S. Department of War
- Conquer Cancer Foundation
This publication has 28 references indexed in Scilit:
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialThe Lancet Oncology, 2016
- Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologiesAnnals of Oncology, 2014
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013
- Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinomaBJU International, 2012
- A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Medical Oncology, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted TherapyJournal of Clinical Oncology, 2009
- Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformationCancer, 2005
- Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaCancer, 2004
- PROGNOSTIC FACTORS AND SURVIVAL OF PATIENTS WITH SARCOMATOID RENAL CELL CARCINOMAJournal of Urology, 2002